Sequenom test volumes may beat expectations by wide margin, says William Blair After conducting checks, William Blair thinks that Sequenom could accession more than 25,000 tests in Q3, easily beating Street expectations. The firm expects the stock to appreciate and it reiterates an Outperform rating on the shares.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.
Subscribe for More Information